In this study, we have shown that antagonists of TNF, IL‐6 and IL‐1 could down‐regulate leptin‐induced ROS production and attenuate RA FLS migration and angiogenesis, which might offer a promising mechanism for clinical treatment of RA. The gene discussed is TNF; the disease is rheumatoid arthritis.